STOCKS TELEGRAPH

Tag: NASDAQ:PHIO

  • Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    The clinical-stage biopharmaceutical company Phio Pharmaceuticals Corp. (NASDAQ: PHIO), which specializes in siRNA-based cancer treatments, saw a sharp rise in stock value after launching a new strategic strategy. As of the latest transaction data, PHIO shares were up 7.42% to $3.18, reflecting investor confidence in the company’s growing emphasis.

    Increasing the Therapeutic Potential of INTASYL

    The business is developing its in-house INTASYL gene silencing technology, which consists of a pipeline of about 30 chemicals at the moment. With its recently revealed strategic plan, Phio hopes to raise awareness of the portfolio’s wider applications.

    This action comes after the current Phase 1b dosage escalation study of PH-762, an INTASYL chemical used to treat skin cancer, showed encouraging interim safety and effectiveness results. Preclinical and clinical evidence suggest that INTASYL may find application in a broader number of therapeutic domains.

    Change in Leadership to Promote Development

    Phio announced significant leadership changes that would take effect on June 9, 2025, in support of these goals. Former Chief Financial Officer Mr. Robert Infarinato has been promoted to Vice President of Strategic Development. Mr. Infarinato will spearhead business development initiatives aimed at extending the INTASYL platform’s strategic reach in his new position.

    With more than thirty years of expertise in operations and finance, Mr. Infarinato has held high-level roles such as Chairman of the Board of Trustees of Abington Health and Executive Vice President and CFO of a global services organization.

    Strengthened Finance Leadership

    Ms. Lisa Carson was appointed Vice President of Finance and Administration at the same time. With more than 20 years of experience in finance leadership, Carson joined Phio in May 2025.

    She previously served as Controller and Vice President of Finance at Prelude Therapeutics being  a key player in the IPO and growth of the business over time. Moreover, her previous roles at TELA Bio and PhaseBio Pharmaceuticals attest to her expertise in biopharma finance operations.

    These key hires demonstrate Phio’s dedication to developing its cutting-edge siRNA technology and increasing shareholder value via focused research and strengthened leadership.

  • Pre-Market Surge For Phio Pharmaceuticals Following Clinical Success

    Pre-Market Surge For Phio Pharmaceuticals Following Clinical Success

    Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) have been sharply rising on the charts following the release of encouraging clinical trial results. Its stock price has grown an astounding 130.18% to $3.89 per share as of the most recent pre-market check.

    PHIO Shared Clinical Studies Showing Favorable Results

    Phio Pharmaceuticals, a clinical-stage biotechnology business, is expanding its range of medications by employing its proprietary INTASYL siRNA gene silencing technology. This strategy aims to improve immune cells’ ability to identify and eliminate cancer cells.

    Today, patients in the second cohort of the current Phase 1b clinical research by Phio Pharmaceuticals showed encouraging pathologic responses. Two patients had a full response, indicating 100% tumor removal, according to the data. 

    Phase 1b Study Progress and Tumor Response Results

    The purpose of the Phase 1b clinical research (NCT 06014086) is to assess the safety and tolerability of administering PH-762 intratumorally to patients who have metastatic melanoma, Merkel cell carcinoma, or advanced types of cutaneous squamous cell carcinoma. Of the patients enrolled, six were diagnosed with cutaneous squamous cell carcinoma, and one with metastatic melanoma.

    The latest data from the second cohort, which includes four patients, demonstrated significant tumor responses. Two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance, while a third reported a partial response with 90% tumor reduction.

    Reassuring Safety Data and Future Outlook

    In addition to the encouraging therapeutic responses, the trial has reported no dose-limiting toxicities or clinically significant adverse events. The intratumoral PH-762 injections have been well tolerated, further bolstering the safety profile of the treatment.

    Phio Pharmaceuticals is hopeful that more people will sign up for the experiment so that larger dosage concentrations of PH-762 may be tested. The company’s future is bright thanks to these encouraging early dosage escalation findings, as Phio Pharmaceuticals keeps up its revolutionary application of INTASYL technology in pursuit of a cancer-free future.

  • Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates

    Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates

    As of the last check during the recent trading session, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares were up 33.81% to $2.36, indicating a big increase in value today. The spike in PHIO stock is due to a recently announced equity offering and positive outcomes from clinical research.

    Inspiration Findings from the PH-762 Clinical Trial

    According to Phio Pharmaceuticals, dosage escalation in the ongoing Phase 1b clinical investigation for PH-762 has been approved by the Safety Monitoring Committee or SMC. The safety and tolerability of this new intratumoral injection treatment are being investigated in patients with advanced Merkel cell carcinoma, melanoma, and cutaneous squamous cell carcinoma.

    Treatment for cutaneous squamous cell carcinoma was administered to the second set of study participants. Two patients who finished treatment showed a partial response with 90% tumor clearance, while one patient had a full response with 100% tumor elimination.

    Plans for Funding and Equity Offering 

    Final agreements for the sale of 437,192 common shares in a registered direct offering at a price of $2.635 per share were signed, according to a separate announcement from Phio Pharmaceuticals. Concurrently, the company will issue unregistered warrants that allow for the purchase of an equivalent number of shares at an exercise price of $2.51 per share. These warrants have a five-year expiry date and an immediate exercise period.

    The offering is expected to generate about $1.15 million in gross sales before expenses when it closes on December 20, 2024. PHIO is in plans to use the net proceeds for operating capital and general corporate purposes.

    The Positive Trends of Phio Pharmaceuticals 

    Phio Pharmaceuticals is setting itself up for expansion with encouraging clinical findings and calculated financial decisions. The latest advancements demonstrate not just PH-762’s promise as a ground-breaking cancer treatment, but also the company’s dedication to developing its pipeline and obtaining the required capital.

  • Market Movers: What changed for these 45 stocks while you were sleeping

    FuelCell Energy Inc. (FCEL) stock soared 7.34% to $4.02 in the pre-market trading. The most recent rating by JP Morgan, on October 08, 2020, is Overweight.

    Blink Charging Co. (NASDAQ: BLNK) shares are trading up 5.5% at $12.86 at the time of writing after the company introduction of its innovative Cable Management Solution for use with both new Blinks charging stations and retrofit installations of its IQ 200 charging stations. Blink’s 52-week range was noted as $1.25 to $14.58.

    Canaan Inc. (CAN) grew over 6.38% at $3.5 in pre-market trading today after the announced its third-quarter earnings results.

    Zomedica Pharmaceuticals Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, rose about 6.25% at $0.119 in pre-market trading Tuesday.

    American Resources Corporation (AREC) stock moved up 6.17 percent to $1.72 in the pre-market trading after the company announced that Mark Jensen, Chairman, and CEO of American Resources Corporation was chosen to attend the Proactive ONE2ONE Strategic Metals Supply Chain Investor Forum on Tuesday, November 10, 2020, at 1:00 PM ET.

    Li Auto Inc. (LI) gained over 6.78% at $37.96 in pre-market trading Tuesday 17 November 2020 after the company announced an upbeat Earnings result.

    Anworth Mortgage Asset Corporation (ANH) is up more than 5.42% at $2.14 in pre-market hours Tuesday 17 November 2020 after the announcement by the company that in accordance with the terms of Anworth’s 8.625% Series A Cumulative Preferred stock, the board of directors declared a Series A Preferred Stock dividend of $0.539063 per share for the fourth quarter of 2020. The stock had jumped over 11.54% to $2.03 in the last trading session.

    Before the trading started on 17 November 2020, Kandi Technologies Group Inc. (KNDI) is up 4.74% to reach $8.4 as the report arrives that it closed a registered direct offering of 9,404,392 units of its securities at a purchase price per Unit of $6.38, generating aggregate gross proceeds to the Company of approximately $60,000,000, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. It has been trading in a 52-week range of $2.17 to $17.40.

    New Concept Energy Inc. (GBR) stock soared 16.48% to $2.12 in the pre-market trading following the announcement of the company’s Q3 2020, fiscal results.

    Vaxart Inc. (NASDAQ: VXRT) shares are trading up 7.36% at $5.98 at the time of writing. The company’s 52-week range was noted as $0.27 to $17.49 as the company said it is hosting a key opinion leader panel call for investors. Analysts have a consensus price target of $17.

    Platinum Group Metals Ltd. (PLG) grew over 3.54% at $2.05 in pre-market trading today.

    Muscle Maker Inc. (GRIL), a Restaurant company, rose about 2.94% at $2.1 in pre-market trading Tuesday after the company announced the launch of its online meal plan delivery service platform.

    Sasol Limited (SSL) stock moved up 3.73 percent to $7.51 in the pre-market trading after the company announced the beneficial operation of the Louisiana low-density polyethylene unit.

    Ocean Power Technologies Inc. (OPTT) gained over 2.23% at $1.83 in pre-market trading Tuesday 17 November 2020 after the company announced receipt of a DeepStar project award to study the deployment and operational requirements of utilizing OPT’s PB3 PowerBuoy to provide remotely controllable zero-carbon power for deepwater subsea oil production applications.

    Waitr Holdings Inc. (WTRH) is up more than 3.26% at $2.85 in pre-market hours Tuesday 17 November 2020 after the company earnings beat analysts’ expectations. The stock had jumped over 5.34% to $2.76 in the last trading session.

    Before the trading started on 17 November 2020, XPeng Inc. (XPEV) is up 6.33% to reach $46.89 after the company announced upbeat operating and financial results as a Public Company. It has been trading in a 52-week range of $17.11 to $51.27.

    Sequans Communications S.A. (SQNS) stock soared 15.84% to $5.34 in pre-market trading. The most recent rating by B. Riley FBR, on May 18, 2020, is a Buy.

    Live Oak Bancshares Inc. (NASDAQ: LOB) shares are trading up 3.51% at $46.89 at the time of writing. The company’s 52-week range was noted as $7.57 to $43.95. Analysts have a consensus price target of $42.

    Yunhong CTI Ltd. (CTIB) grew over 27.62% at $2.31 in pre-market trading today after the company announced production capacity expansion at its lake Barrington, Illinois facility to meet increased customer demand.
    .

    Neptune Wellness Solutions Inc. (NEPT), a Drug Manufacturers – Specialty & Generic company, rose about 15.71% at $2.21 in pre-market trading Tuesday after the firm received Over US$100 million in purchase orders.

    Gevo Inc. (GEVO) stock moved up 6.8 percent to $1.1 in the pre-market trading after the company posted Q3 results.

    So-Young International Inc. (SY) gained over 5.0% at $14.28 in pre-market trading Tuesday 17 November 2020 after the company said that it will report third-quarter 2020 financial results on November 25, 2020.

    Sequential Brands Group Inc. (SQBG) is up more than 41.84% at $10.0 in pre-market hours Tuesday 17 November 2020. The stock had jumped over 2.92% to $7.05 in the last trading session as the company announced its Q3, 2020 Earnings results.

    Before the trading started on 17 November 2020, MICT Inc. (MICT) is up 4.55% to reach $1.61. It has been trading in a 52-week range of $0.44 to $8.45.

    The Macerich Company (MAC) stock plunged -0.11% to $9.03 in the pre-market trading after the company’s announcement of its earnings results. The most recent rating by Morgan Stanley, on September 14, 2020, is an Underweight.

    Aphria Inc. (NASDAQ: APHA)c shares are trading down 0.0% at $5.8 at the time of writing after the company announced that its management will host a fireside chat discussion at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 9:05 a.m. ET. The company’s 52-week range was noted as $1.95 to $6.44.

    NIO Limited (NIO) grew over 3.23% at $47.05 in pre-market trading today as the company is set to announce its earnings results.

    BIO-key International Inc. (BKYI), a Security & Protection Services company, rose about 6.32% at $0.444 in pre-market trading Tuesday following the announcement of its quarterly earnings results.

    ObsEva SA (OBSV) stock moved up 6.64 percent to $2.25 in the pre-market trading as the company reported positive topline results of the PROLONG proof-of-concept trial of ebopiprant for treatment of preterm labor.

    Schrodinger Inc. (SDGR) gained over 5.29% at $61.9 in pre-market trading Tuesday 17 November 2020 as the company revealed third fiscal quarter results and business update.

    Lexicon Pharmaceuticals Inc. (LXRX) is up more than 51.16% at $1.95 in pre-market hours Tuesday 17 November 2020 after the company announced its participation in the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020. The stock had jumped over 1.57% to $1.29 in the last trading session.

    Before the trading started on 17 November 2020, JOYY Inc. (YY) is up 7.76% to reach $103.0 after the report that Baidu has acquired JOYY for $3.6 billion. It has been trading in a 52-week range of $41.33 to $104.17.

    Bristol-Myers Squibb Company (BMY) stock soared 2.82% to $66.32 in the pre-market trading after Bristol Myers Squibb offered a regulatory update on Lisocabtagene Maraleucel. The most recent rating by Societe Generale, on November 16, 2020, is a Buy.

    Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares are trading up 5.33% at $2.37 at the time of writing as the firm announced Q3 earnings results and business update. The company’s 52-week range was noted as $1.60 to $13.69. Analysts have a consensus price target of $4.

    PG&E Corporation (PCG) grew over 2.95% at $11.88 in pre-market trading today after the announcement made by the company that CEO Jeff Ramson will join a panel at the Virtual Fall Investor Summit taking place on November 16- 18, 2020.

    strong>Niu Technologies (NIU), an Auto Manufacturers company, rose about 4.52% at $34.47 in pre-market trading Tuesday.

    Avinger Inc. (AVGR) stock moved up 3.87 percent to $0.2789 in the pre-market trading after the company posted Q3 results.

    T-Mobile US Inc. (TMUS) gained over 3.23% at $132.8 in pre-market trading Tuesday 17 November 2020 after the report that Peter Osvaldik, executive vice president & chief financial officer, Neville Ray, president of technology, and Matt Staneff, executive vice president & chief marketing officer of T-Mobile US, Inc. (NASDAQ: TMUS), will present and provide a business update on Thursday, November 19, 2020, at 1:20 p.m. Eastern Time (ET) at the Morgan Stanley European Technology, Media & Telecom Conference.

    Tesla Inc. (TSLA) is up more than 12.45% at $458.9 in pre-market hours Tuesday 17 November 2020 after a report of the company joining the S&P 500. The stock had dropped over -0.10% to $408.09 in the last trading session.

    Before the trading started on 17 November 2020, CHF Solutions Inc. (CHFS) is up 2.31% to reach $6.2 as the company announced a 52% rise in Revenue in the earnings report. It has been trading in a 52-week range of $5.80 to $38.70.

    Aerie Pharmaceuticals Inc. (AERI) stock soared 3.94% to $13.46 in the pre-market trading after the company received positive CHMP opinion for roclanda in the European Union. The most recent rating by BofA Securities, on October 19, 2020, is an Underperform.

    Venus Concept Inc. (NASDAQ: VERO) shares are trading up 5.31% at $2.18 at the time of writing as the company revealed its Q3 results and business update. The company’s 52-week range was noted as $2.02 to $9.00. Analysts have a consensus price target of $6.

    Qudian Inc. (QD) grew over 2.6% at $1.58 in pre-market trading today.

    Celsion Corporation (CLSN), a Biotechnology company, rose about 3.77% at $0.55 in pre-market trading Tuesday as the company revealed its quarterly Earnings report.

    Tencent Music Entertainment Group (TME) stock moved up 2.98 percent to $16.58 in the pre-market trading.

    Net Element Inc. (NETE) is up more than 3.27% at $7.59 in pre-market hours Tuesday 17 November 2020 as the company reported its Q3 earnings results. The stock had dropped over -3.92% to $7.35 in the last trading session.